Alkermes (FRA:8AK) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8AK Alkermes PLC FRA:8AK
72 GF Score
Price €45.08
GF Value €27.70
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Alkermes Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Alkermes Valuation Rank Related Terms

FRA:8AK
72GF Score
Alkermes PLC FRA:8AK
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alkermes (FRA:8AK) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of €45.08 is trading 62.7% above its estimated GF Value™ of €27.70. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for FRA:8AK:

  • Valuation Rank:
  • GF Value™: €27.70 vs. price of €45.08 (62.7% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the FRA:8AK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkermes Business Description

Other Exchanges ALKS:USA
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
72GF Score

Get the complete analysis for FRA:8AK

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.08
Price
€27.70
GF Value